HOME › DRUGS › OPORTUZUMAB MONATOX
ACTIVE SUBSTANCE / INN

OPORTUZUMAB MONATOX

Brand name(s): Oportuzumab monatox DLRC Pharma Services
EMA LISTED
APPLICATION WITHDRAWN
Urologic Neoplasms;Urinary Bladder Neoplasms
ACTIVE SUBSTANCE
Oportuzumab Monatox
REGULATORS
EMA
SPONSORS / MAH
DLRC Pharma Services Ltd
TOTAL APPLICATIONS
1
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
Oportuzumab monatox DLRC Pharma ServicesDLRC Pharma Services LtdApplication withdrawnUrologic Neoplasms;Urinary Bladder Neoplasms

FULL INTELLIGENCE ON OPORTUZUMAB MONATOX

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →